Focused on the development of innovative
drugs for the treatment of chronic diseases
of the skin.
drugs for the treatment of chronic diseases
of the skin.
Connect With Us
Comments
Press Releases
April 2013 - Scioderm's SD-101 Receives Breakthrough Therapy Designation from FDA for Treatment of Epidermolysis Bullosa
April 2013 - Scioderm closes $16 million in series A financing
Feb 2013 - Scioderm’s Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA
June 2012 - Scioderm Announces Positive Phase II Data of Topical SD-101 on Wound Closure and Reduction of Lesions and Blisters in Children with Epidermolysis Bullosa (EB)